Chen Dong-Qin, Pan Ban-Zhou, Huang Jia-Yuan, Zhang Kai, Cui Shi-Yun, De Wei, Wang Rui, Chen Long-Bang
Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, China.
Oncotarget. 2014 May 30;5(10):3333-49. doi: 10.18632/oncotarget.1948.
Chemoresistance is one of the most significant obstacles in lung adenocarcinoma (LAD) treatment, and this process involves genetic and epigenetic dysregulation of chemoresistance-related genes. Previously, we have shown that restoration of microRNA (miR)-200b significantly reverses chemoresistance of human LAD cells by targeting E2F3. However, the molecular mechanisms involved in the silencing of miR-200b are still unclear. Here we showed that histone deacetylase (HDAC) inhibitors could restore the expression of miR-200b and reverse chemoresistant phenotypes of docetaxel-resistant LAD cells. HDAC1/4 repression significantly increased miR-200b expression by upregulating histone-H3 acetylation level at the two miR-200b promoters partially via a Sp1-dependent pathway. Furthermore, silencing of HDAC1/4 suppressed cell proliferation, promoted cell apoptosis, induced G2/M cell cycle arrest and ultimately reversed in vitro and in vivo chemoresistance of docetaxel-resistant LAD cells, at least partially in a miR-200b-dependent manner. HDAC1/4 suppression-induced rescue of miR-200b contributed to downregulation of E2F3, survivin and Aurora-A, and upregulation of cleaved-caspase-3. HDAC1/4 levels in docetaxel-insensitive human LAD tissues, inversely correlated with miR-200b, were upregulated compared with docetaxel-sensitive tissues. Taken together, our findings suggest that the HDAC1/4/Sp1/miR-200b/E2F3 pathway is responsible for chemoresistance of docetaxel-resistant LAD cells.
化疗耐药是肺腺癌(LAD)治疗中最显著的障碍之一,这一过程涉及化疗耐药相关基因的遗传和表观遗传失调。此前,我们已经表明,通过靶向E2F3,微小RNA(miR)-200b的恢复可显著逆转人LAD细胞的化疗耐药性。然而,miR-200b沉默所涉及的分子机制仍不清楚。在此,我们表明组蛋白去乙酰化酶(HDAC)抑制剂可恢复miR-200b的表达,并逆转多西他赛耐药LAD细胞的化疗耐药表型。HDAC1/4的抑制通过部分依赖Sp1的途径上调两个miR-200b启动子处的组蛋白H3乙酰化水平,从而显著增加miR-200b的表达。此外,HDAC1/4的沉默抑制细胞增殖,促进细胞凋亡,诱导G2/M期细胞周期阻滞,并最终逆转多西他赛耐药LAD细胞的体内外化疗耐药性,至少部分是以miR-200b依赖的方式。HDAC1/4抑制诱导的miR-200b挽救有助于下调E2F3、存活素和Aurora-A,并上调裂解的半胱天冬酶-3。与多西他赛敏感组织相比,多西他赛不敏感的人LAD组织中HDAC1/4水平上调,且与miR-200b呈负相关。综上所述,我们的研究结果表明HDAC1/4/Sp1/miR-200b/E2F3通路与多西他赛耐药LAD细胞的化疗耐药有关。